Cytoskeletal protein KRT14 governs cisplatin resistance by modulating eIF4H-dependent ACOX2 translation and lipid metabolism in bladder cancer.

ABSTRACT: Cisplatin-based chemotherapy remains a mainstay for the treatment of bladder cancer (BLCA); however, its clinical efficacy is frequently compromised by the emergence of chemoresistance, which leads to poor patient outcomes. Although known mechanisms-such as alterations in drug efflux, DNA repair, and key signaling pathways-have been implicated, they fail to fully explain the clinical complexity of cisplatin resistance, indicating that additional molecular drivers remain undiscovered. Keratin 14 (KRT14), an intermediate filament protein associated with aggressive BLCA subtypes, is consistently upregulated in cisplatin-resistant tumors, yet its precise mechanistic role in resistance remains unclear. In this study, we elucidate the functional contribution of KRT14 to cisplatin resistance in B

SUBMITTER: Liu S 

PROVIDER: S-EPMC12847778 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature